Janssen
Image: Lung Cancer Cells

Welcome to WCLC 2020

PLEASE NOTE: Materials will be available on a rolling basis as soon as individual embargoes are lifted.

Select a product to view

Amivantamab
Lazertinib
Disease-state
Erdafitinib

Amivantamab

View the scientific materials

Oral Presentation Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Joshua K. Sabari1; Catherine A. Shu2; Keunchil Park3; Natasha B. Leighl4; Paul Mitchell5;  Sang-We Kim6; Jong-Seok Lee7; Dong-Wan Kim8; Santiago Viteri9; Alexander I. Spira10; Ji-Youn Han11; José Trigo12; Chee Khoon Lee13; Ki Hyeong Lee14; Nicolas Girard15; Tsung-Ying Yang16; Koichi Goto17; Rachel E. Sanborn18; James Chih-Hsin Yang19; Joshua C. Curtin20; John Xie20; Amy Roshak20; Meena Thayu20; Roland E. Knoblauch20; Byoung Chul Cho21

View Slides View Video
Poster PAPILLON: A Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon 20ins NSCLC

Trishala Agrawal; Eunice Artis; John Xie; Archan Bhattacharya; Nahor Haddish-Berhane; Tammy Gopen; Joshua C. Curtin; Jayaprakash Karkera;
Amy Rosha; Roland E. Knoblauch; and Kiran Patel

View Slides
Poster A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-mutated NSCLC

Koichi Goto1; Toyoaki Hida2; Nobuyuki Funami3; Ryota Iwasawa3; Sachiko Mita3; Aimi Yamashita3; Leonardo Trani4; Janine Mahoney4; Nahor Haddish-Berhane4; John Xie4; Amy Roshak4; Roland E. Knoblauch4; and Yuichiro Ohe5

View Slides
Poster MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Martin Shreeve; Melissa Martinez; Remy B. Verheijen; Seema N. Sethi; Kellen Meadows; Renee Pierson; John Xie; Tao Sun; Nahor Haddish-Berhane; Dona Pang; Joshua C. Curtin; Jayaprakash Karkera; Amy Roshak; Roland E. Knoblauch; and Kiran Patel

View Slides

Lazertinib

View the scientific materials

Poster Cardiac Safety Assessment of Lazertinib in Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer

Nahor Haddish-Berhane1; Byoung Chul Cho2; Myung-Ju Ahn3; Ji-Youn Han4; Sang-We Kim5; Ki Hyeong Lee6; Eun Kyung Cho7; Jaydeep Mehta1; John Xie1; S. Martin Shreeve8; Roland E. Knoblauch1; John Freeman9; Amy Roshak1; Seong Bok Jang10; Hana Lee10; Seonmi Kang10; Kyeong Bae Kim11; and Se-Woong Oh11

View Slides
Poster A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-mutated NSCLC

Koichi Goto1; Toyoaki Hida2; Nobuyuki Funami3; Ryota Iwasawa3; Sachiko Mita3; Aimi Yamashita3; Leonardo Trani4; Janine Mahoney4; Nahor Haddish-Berhane4; John Xie4; Amy Roshak4; Roland E. Knoblauch4; and Yuichiro Ohe5

View Slides
Poster MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

S. Martin Shreeve; Melissa Martinez; Remy B. Verheijen; Seema N. Sethi; Kellen Meadows; Renee Pierson; John Xie; Tao Sun; Nahor Haddish-Berhane; Dona Pang; Joshua C. Curtin; Jayaprakash Karkera; Amy Roshak; Roland E. Knoblauch; and Kiran Patel

View Slides

Disease-state

View the scientific materials

Mini Oral Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations

Nicolas Girard1; Lyudmila Bazhenova2; Anna Minchom3; Sai-Hong Ignatius Ou4; Shirish M. Gadgeel5; José Trigo6; Santiago Viteri7; Gang Li8; Parthiv Mahadevia8; Anil Londhe8; Daniel Backenroth8; Tracy Li8; Joshua M. Bauml9

View Slides View Video
Featured Poster Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets

Joshua M. Bauml1; Santiago Viteri2; Anna Minchom3; Lyudmila Bazhenova4; Sai-Hong Ignatius Ou5; Michael Schaffer6; Nicholas LeCroy6; Ralph Riley6; Parthiv Mahadevia6; Nicolas Girard7

View Slides View Video
Poster Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review

Heather Burnett1; Helena Emich2; Chris Carroll3; Naomi Stapleton2; Parthiv Mahadevia4; Tracy Li4

View Slides

Erdafitinib

View the scientific materials

Poster A Phase 2 Study of Erdafitinib in Patients With Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

Shubham Pant1; Josep Tabernero2; Christophe Massard3; Gopa Iyer4; Olaf Witt5; Toshihiko Doi6; Shukui Qin7; Christine Lu-Emerson8; Darren Hargrave9; Javier Garcia-Corbacho10; Shonda Little11; Qi Xia11; Ademi Santiago-Walker11; Christopher Moy11; Constance Hammond11; Hussein Sweiti11; Martin Schuler12

View Slides

The safety and efficacy of the investigational use of these products have not been determined. 
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.

Amivantamab includes technology licensed from Genmab A/S.

Lazertinib is being developed pursuant to a collaboration and licence agreement with Yuhan Corporation.

Janssen Logo